A Rapid Review on the Efficacy and Safety of Pharmacological Treatments for Chagas Disease
Chagas disease remains a neglected tropical disease, causing significant burden in the Americas and countries that receive immigrants from endemic nations. Current pharmaceutical treatments are suboptimal, not only varying drastically in efficacy, depending on the stage of disease, but also presenti...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-07-01
|
Series: | Tropical Medicine and Infectious Disease |
Subjects: | |
Online Access: | https://www.mdpi.com/2414-6366/6/3/128 |
id |
doaj-c384e4b9ea52494982f4bcaf6edcfeaa |
---|---|
record_format |
Article |
spelling |
doaj-c384e4b9ea52494982f4bcaf6edcfeaa2021-09-26T01:34:14ZengMDPI AGTropical Medicine and Infectious Disease2414-63662021-07-01612812810.3390/tropicalmed6030128A Rapid Review on the Efficacy and Safety of Pharmacological Treatments for Chagas DiseaseCody J Malone0Immaculate Nevis1Eduardo Fernández2Ana Sanchez3Department of Health Sciences, Faculty of Applied Health Sciences, Brock University, St. Catharines, ON L2S 3A1, CanadaDepartment of Health Sciences, Faculty of Applied Health Sciences, Brock University, St. Catharines, ON L2S 3A1, CanadaDepartment of Health Sciences, Faculty of Applied Health Sciences, Brock University, St. Catharines, ON L2S 3A1, CanadaDepartment of Health Sciences, Faculty of Applied Health Sciences, Brock University, St. Catharines, ON L2S 3A1, CanadaChagas disease remains a neglected tropical disease, causing significant burden in the Americas and countries that receive immigrants from endemic nations. Current pharmaceutical treatments are suboptimal, not only varying drastically in efficacy, depending on the stage of disease, but also presenting significant risk of adverse events. The objective of this review is to provide a timely update on the efficacy and safety of current trypanocidals. Eligible studies published from January 2015 to December 2020 were retrieved by one reviewer from six electronic databases. Ana-lysis was done with review management software and risk of bias was assessed using tools appropriate for the type of study (i.e., experimental or observational). Thirteen studies (10 observational and three RCTs) were included in the analysis. All 13 studies tested Benznidazole (BNZ) or Nifurtimox (NFX), and two studies also tested Posaconazole (POS) or E1224 (Ravucanazole). BNZ was found to be the most efficacious trypanocidal drug compared to Nifurtimox, POS, and E1224; it also resulted in the highest percentage of adverse effects (AEs) and treatment discontinuation due to its toxicity. Adults experienced higher frequency of neurological AEs while taking BNZ or NFX compared to children. Children had a higher frequency of general AEs compared to adults while taking BNZ. Overall, BNZ is still the most efficacious, but development of new, less toxic drugs is paramount for the quality of life of patients. Studies testing combination therapies and shorter regimens are needed, as is the devising of better clinical parameters and laboratory biomarkers to evaluate treatment efficacy. Considering the variability in methodology and reporting of the studies included in the present analysis, we offer some recommendations for the improvement and replicability of clinical studies investigating pharmacological treatment of Chagas disease. These include full disclosure of methodology, standardization of outcome measures, and always collecting and reporting data on both the efficacy of trypanocidals and on safety outcomes.https://www.mdpi.com/2414-6366/6/3/128Chagas diseaseAmerican Trypanosomiasistrypanocidalsrapid review |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Cody J Malone Immaculate Nevis Eduardo Fernández Ana Sanchez |
spellingShingle |
Cody J Malone Immaculate Nevis Eduardo Fernández Ana Sanchez A Rapid Review on the Efficacy and Safety of Pharmacological Treatments for Chagas Disease Tropical Medicine and Infectious Disease Chagas disease American Trypanosomiasis trypanocidals rapid review |
author_facet |
Cody J Malone Immaculate Nevis Eduardo Fernández Ana Sanchez |
author_sort |
Cody J Malone |
title |
A Rapid Review on the Efficacy and Safety of Pharmacological Treatments for Chagas Disease |
title_short |
A Rapid Review on the Efficacy and Safety of Pharmacological Treatments for Chagas Disease |
title_full |
A Rapid Review on the Efficacy and Safety of Pharmacological Treatments for Chagas Disease |
title_fullStr |
A Rapid Review on the Efficacy and Safety of Pharmacological Treatments for Chagas Disease |
title_full_unstemmed |
A Rapid Review on the Efficacy and Safety of Pharmacological Treatments for Chagas Disease |
title_sort |
rapid review on the efficacy and safety of pharmacological treatments for chagas disease |
publisher |
MDPI AG |
series |
Tropical Medicine and Infectious Disease |
issn |
2414-6366 |
publishDate |
2021-07-01 |
description |
Chagas disease remains a neglected tropical disease, causing significant burden in the Americas and countries that receive immigrants from endemic nations. Current pharmaceutical treatments are suboptimal, not only varying drastically in efficacy, depending on the stage of disease, but also presenting significant risk of adverse events. The objective of this review is to provide a timely update on the efficacy and safety of current trypanocidals. Eligible studies published from January 2015 to December 2020 were retrieved by one reviewer from six electronic databases. Ana-lysis was done with review management software and risk of bias was assessed using tools appropriate for the type of study (i.e., experimental or observational). Thirteen studies (10 observational and three RCTs) were included in the analysis. All 13 studies tested Benznidazole (BNZ) or Nifurtimox (NFX), and two studies also tested Posaconazole (POS) or E1224 (Ravucanazole). BNZ was found to be the most efficacious trypanocidal drug compared to Nifurtimox, POS, and E1224; it also resulted in the highest percentage of adverse effects (AEs) and treatment discontinuation due to its toxicity. Adults experienced higher frequency of neurological AEs while taking BNZ or NFX compared to children. Children had a higher frequency of general AEs compared to adults while taking BNZ. Overall, BNZ is still the most efficacious, but development of new, less toxic drugs is paramount for the quality of life of patients. Studies testing combination therapies and shorter regimens are needed, as is the devising of better clinical parameters and laboratory biomarkers to evaluate treatment efficacy. Considering the variability in methodology and reporting of the studies included in the present analysis, we offer some recommendations for the improvement and replicability of clinical studies investigating pharmacological treatment of Chagas disease. These include full disclosure of methodology, standardization of outcome measures, and always collecting and reporting data on both the efficacy of trypanocidals and on safety outcomes. |
topic |
Chagas disease American Trypanosomiasis trypanocidals rapid review |
url |
https://www.mdpi.com/2414-6366/6/3/128 |
work_keys_str_mv |
AT codyjmalone arapidreviewontheefficacyandsafetyofpharmacologicaltreatmentsforchagasdisease AT immaculatenevis arapidreviewontheefficacyandsafetyofpharmacologicaltreatmentsforchagasdisease AT eduardofernandez arapidreviewontheefficacyandsafetyofpharmacologicaltreatmentsforchagasdisease AT anasanchez arapidreviewontheefficacyandsafetyofpharmacologicaltreatmentsforchagasdisease AT codyjmalone rapidreviewontheefficacyandsafetyofpharmacologicaltreatmentsforchagasdisease AT immaculatenevis rapidreviewontheefficacyandsafetyofpharmacologicaltreatmentsforchagasdisease AT eduardofernandez rapidreviewontheefficacyandsafetyofpharmacologicaltreatmentsforchagasdisease AT anasanchez rapidreviewontheefficacyandsafetyofpharmacologicaltreatmentsforchagasdisease |
_version_ |
1716868720677093376 |